Nivolumab/Ipilimumab Combination Data Promising in MSI-H/dMMR mCRC
August 27th 2019Heinz-Josef Lenz, MD, discusses the significance of the latest updates in the CheckMate 142 trial exploring an immunotherapy treatment combination in patients with metastatic colorectal cancer whose tumors are microsatellite instability–high or mismatch repair deficient.